Introduction: Ventricular tachycardia (VT) acceleration due to antitachycardia pacing
| INTRODUCTION
Implantable cardioverter defibrillators (ICDs) play a significant role in the diagnosis and treatment of malignant ventricular tachyarrhythmias in patients at high risk of sudden cardiac death. 1 Although ICD shocks could terminate those arrhythmias immediately, they would result in both physical and psychological damages and even increase the mortality and hospitalization as proved in some previous studies.
2 -4 As a method of painless therapy and a supplement of ICD shocks, antitachycardia pacing (ATP) has been demonstrated to be as effective as ICD shocks with no increase in mortality and improve patients' quality of life. 5 However, not all ATPs could terminate ventricular arrhythmias and some ATPs may even lead to the acceleration of ventricular tachycardias (VTs) or degeneration of those to ventricular fibrillations (VFs), which might result in more ICD shocks or even "ICD storms." According to previous studies, the rate of ATP acceleration ranged from 1.2% to 21%, [5] [6] [7] [8] (i) age<18, (ii) without structural heart disease, (iii) with ionic channel disease, (iv) ICD or CRT-D implantation because of primary prevention, (v) without ATP therapies during the follow-up, (vi) only with ATP therapies due to polymorphic VTs, and (vii) only with inappropriate ICD therapies due to supraventricular tachycardias.
The study complied with the Declaration of Helsinki and followed acceptance of the protocol by the institutional review board. All the patients provided informed consent, and the enrollment is shown in Figure 1 .
| Data collection
Clinical baseline characteristics and implantation records were collected during patients' hospitalization. During the follow-up, all available stored episodes were collected, including VT cycle length (VTCL), mean variation in VTCL, variation degree of VTCL, and number of VT morphologies recorded in electrograms (EGMs). These episodes were analyzed by 2 experienced physicians. Episodes exceeding the storage of device memory due to electrical storms were excluded as they could not be read. If electrophysiological (EP) study was performed before device implantation or catheter ablation during the follow-up because of ventricular arrhythmias, the EP data would also be collected.
| Device implantation and programming
All patients received implantations of single-chamber, dual-chamber ICD or CRT-D (Medtronic, Boston Scientific, and Biotronik). The | 37 right ventricular intravenous leads were positioned either in apex or in septum. The devices were programmed with either 2 or 3 tachyarrhythmia detection zones based on the preoperative VT rate.
Moreover, ATPs were chosen as the first-line therapy for monomor- 
| Classification and definitions
ATP acceleration was defined as VTCL decreased by>10% or VT degenerated to ventricular flutter or VF after ATP attempt. ATP-successful therapy was defined as both the ventricular rhythm was converted and the termination standard of the device was met after ATP therapy of VT. ATP-nonresponse therapy referred to those episodes with increase or no change in VT cycle length after ATP therapy ( Figure 2 ). In addition, followings are the instructions of several parameters that will be estimated in this study.
| VTCL
VT cycle length, defined by the mean value of the last 12 RR intervals preceding the first ATP therapy.
| M-VTCL
Mean variation in VTCL, defined by the mean difference between 2 adjacent RR intervals in 13 RR intervals before the first ATP delivery. 
| Prop-nonresponse
The proportion of ATP-nonresponse episodes, which was calculated by dividing the numbers of ATP-nonresponse episodes by the total numbers of ATP episodes in each individual.
| Study design
Patients were classified into 2 groups according to the existence of ATP acceleration. Those who experienced at least 1 ATP acceleration episode were allocated to acceleration group, while those without were allocated to nonacceleration group. Episodes were also divided into 2 groups according to the existence of ATP acceleration:
ATP acceleration group and ATP nonacceleration group. The ATP nonacceleration group was further divided into 2 subgroups: ATP success group and ATP-nonresponse group. Thereafter, we analyzed different information and parameters in patient grouping and episode grouping, respectively. VT morphologies recorded in EGMs during the follow-up was also more in the acceleration group. In addition, the proportion of ATPnonresponse episodes was greater in acceleration group than in nonacceleration group (Table 1) . By the logistic regression analysis, number of VT morphologies in EGMs was proved to be a predictor of ATP acceleration (Table 2A) . ROC curve was generated to estimate significance of different numbers of VT morphologies in ATP acceleration. The cutoff point was 1 with the best sensitivity and specificity of 72.7% and 77.3%, respectively (AUC 0.79, P < .001) ( Figure 3A ). 
| Device therapies

| Analysis by ATP episodes
The different parameters between 2 groups of episodes are shown in Table 3 . Based on the univariate analysis, the logistic regression analysis showed that the VTCL and mean variation in VTCL were both predictors of ATP acceleration (Table 2B) . ROC curves were performed to estimate significance of different VTCL and mean variation in VTCL in ATP acceleration. The cutoff point of VTCL was 347 ms with the optimal sensitivity and specificity of 82.5% and 47.6%, respectively (AUC 0.67, P < .001) ( Figure 3B ). The cutoff point of mean variation in VTCL was 7.3 ms with the best sensitivity and specificity of 77.5% and 56.7%, respectively (AUC 0.66, P < .001) ( Figure 3C ).
| Analysis of ATP stimulation
Parameters of different ATP stimulation between ATP acceleration group and ATP success group are compared in Table 4 . We found that the pulse number of burst stimulation was more in acceleration group than in success group within both the overall events and those with VTCL<347 ms. The similar findings were seen in the episodes that could be terminated by one-sequence ATP delivery (Table 5 ).
| DISCUSSION
The purpose of this study was to find the factors that may lead to VT acceleration by ATP therapies. It showed that number of VT morphologies recorded in EGMs, VTCL, and mean variation in VTCL were the risk factors that could predict ATP acceleration.
Besides, patients with more morphologies of induced VTs during EP test were more likely to experience ATP acceleration. In addition, for VT with cycle length less than 347 ms, burst stimulation with more pulse numbers was more likely to cause ATP acceleration.
| Incidence of ATP acceleration
Based on previous researches, the acceleration rate in spontaneous VT was found no more than 7% 13 and the rate of 3.7% in our study was similar to those studies. Although it seemed to be low, most of the accelerated episodes were eventually terminated by shocks, which could do greater harm to patients. Therefore, it is indispensable to decrease the acceleration incidence in order to relieve patients' agony.
| Number of VT morphologies and ATP acceleration
This study showed that the more number of VT morphologies, the higher rate of ATP acceleration. Clemens et al 14 reported that, in patients with secondary prevention of ICD implantation due to monomorphic VT, the acceleration of VT by ATP was 1.1%, 3.2%, or 8.1% with 1, 2, 3, or more morphologies of VT, respectively. Our study found that if a number of VT morphologies were ≥2 in a single patient during the follow-up, acceleration was easier to be caused with a sensitivity and specificity of 72.7% and 77.3%, respectively.
Therefore, it seems not reasonable to switch on ATP in patients with
≥2 morphologies of VT, and antiarrhythmic drugs (AADs) and catheters ablation should be performed to eliminate VTs as soon as possible.
| VTCL and ATP acceleration
Most researches suggested that ATP acceleration was correlated with short VTCL. 6, 8, 15 It has been demonstrated that reentrant VT responds better to ATP therapy. 13 
| Variation in VTCL and ATP acceleration
Our findings showed that VTs with larger cycle length variation were more likely to be accelerated by ATP stimulation. However, it was different in the study by Jimenez-Candil et al, 12 in which with the increase in variation degree of VTCL, the acceleration incidence decreased. The mechanism of VTCL variation contributing to ATP acceleration is not clear. The discrepancy between 2 studies may be due to the disease entities. 62% of the enrolled patients in their study had coronary artery diseases (CADs), which increased the likelihood of spontaneous termination of VT in patients with higher degree of RR interval fluctuations. 18 However, in the current study, nonischemic structural heart diseases took a large proportion ATP pulse width (ms) 1.6 (1.6, 1.6), n = 17 1.6 (1.5, 1.6), n = 274 .007
Odds ratio 95% Confidence interval P value
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Pulse number (90.9%). Besides, it has been reported that substrate of ischemic heart disease is more stable than that of nonischemic heart disease. 19 The pathological changes in nonischemic heart disease are progressively developing and the substrate is more complex which might cause the instability of VTCL and more incidence of ATP acceleration.
T A B L E 5 A, Analysis of ATP stimulation in one-sequence ATP episodes; B, analysis of ATP stimulation in one-sequence ATP episodes with VTCL<347 ms; C, multivariate analysis (logistic regression) of ATP acceleration predictors by burst stimulation ATP pulse width (ms) 1.6, n = 12 1.5 (1.5, 1.6), n = 240 <.001
Odds ratio 95% 16 In a study with induced VT, with more pulses in ramp stimulation, the incidence of ATP acceleration was higher, but there were no similar findings in burst stimulation. 15 In spontaneous VT study, Nasir et al 20 found no difference between different burst numbers in ATP acceleration either. However, ADVANCE-D trial 21 showed that the incidences of ATP acceleration increased with more burst pulses in both fast VT episodes and overall VT episodes. Unfortunately, they both failed to show statistical significance. Our study suggested that burst pulse numbers affected the result of ATP therapy per se. In VT with cycle length<347 ms, acceleration was more likely to be caused by burst stimulation with higher pulse number.
| Clinical implications
In our study, number of VT morphologies, VT cycle length (VTCL), and variation in VTCL were proved to be risk factors predicting ATP acceleration, and VTs with VTCL less than 347 ms were more likely to be accelerated by burst stimulation with more pulse numbers.
Therefore, more considerations should be taken to reprogram ATP therapies for patients with such risk factors, as to lower or eliminate the incidence of VT acceleration by ATP therapies. For instance, radical ATP settings should not be performed in patients with VT of faster heart rate and more numbers of morphologies.
| Study limitations
First, this study is retrospective and nonrandomized. ATP algorithms were programmed based on individual empirical discretion and previous clinical studies which might cause bias. During the follow-up, ATP algorithms might also be adjusted due to the occurrence of VT episodes. Thus, more randomized controlled trials should be conducted to further confirm these results. Second, due to the limitation of device memory, we did not get whole ATP episodes in patients, which might influence grouping of patients and analysis of data. Third, compared with the control group, the sample size of ATP acceleration episodes was too small, which may weaken the statistical power, although we had used rank sum test and Fisher's exact test to minimize the effect. Fourth, AADs were not unified and might be changed during the follow-up, so the influence of AADs to the ATP therapy was inevitable. Therefore, more studies are needed to standardize regimen of drug therapies in order to get more precise results.
| CONCLUSIONS
We concluded that in patients of structural heart disease with ICD or CRT-D implantation for secondary prevention, number of VT morphologies recorded in EGMs, VTCL, and its mean variation are risk factors predicting ATP acceleration. VT with cycle length<347 ms is more likely to get acceleration by burst stimulation with more pulse numbers. These findings provide the evidence to optimize ATP reprogramming or choose other invasive or noninvasive methods for the purpose of preventing ATP acceleration.
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